ivonescimab

mountain climb steep cliff climber struggle

Previewing Akeso's high-stakes ASCO plenary for PD-1/VEGF

If successful, ivonescimab would be the first regimen to show a survival benefit over a PD-1/chemotherapy combo in first-line NSCLC in a phase 3 trial.

Angus Liu May 27, 2026 11:25am

ASCO: Merck, Kelun's sac-TMT combo beats Keytruda by 65% on PFS

May 21, 2026 5:00pm

Close up shot of the target from a dart game

Akeso details ivonescimab's 1st overall survival win

Nov 7, 2025 11:30am

Akeso, Summit's ivonescimab ups PD-1 in chemo combo in 1L NSCLC

Oct 19, 2025 10:45am

Graphic of a fork in the road with arrows pointing in either direction

Editor's Corner—Summit must submit to Big Pharma, stat

Sep 10, 2025 2:50pm

Summit's global PD-1xVEGF data show new promising OS trend

Sep 7, 2025 3:30am